167 effect of gastrointestinal hormones on the growth of gastrointestinal tumor cells in vitro

Vuillot, Marie-ThérèSe; Kobori, Oichiro; Martin, F.

doi:10.1016/0022-4731(83)91667-9

Journal of Steroid Biochemistry

1983

DOI: 10.1016/0022-4731(83)91667-9

|View full text |Cite

167 effect of gastrointestinal hormones on the growth of gastrointestinal tumor cells in vitro

Marie-ThérèSe Vuillot¹,

Oichiro Kobori²,

F. Martin³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1990

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several gastrointestinal hormones can stimulate the growth of exocrine pancreatic and gastrointestinal tumours (Johnson, 1981;Townsend et al, 1981;Viullot et al, 1983;Lamers, 1987;Lamers & Jansen, 1988;Schally, 1988). The secretion of these hormones and some growth factors can be suppressed by somatostatin or its analogues (Adrian et al, 1981;Schally, 1988).…”

mentioning

confidence: 99%

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

Klijn

Hoff²,

Planting³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth of experimental pancreatic tumours. Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal (n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 lAg of the somatostatin analogue Sandostatin . All patients had an extensive tumour load and 13 were pretreated with chemotherapy. Before Sandostatin treatment the patients with pancreatic cancer showed a higher mean plasma concentration of GH (P<0.05) and a lower concentration of 'total' somatomedin-C (P < 0.005) compared with patients with colorectal cancer; there was no significant difference betwen these two groups in plasma levels of directly assayable somatomedin-C, EGF/TGF-a, insulin and prolactin. Within 3 days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH levels), but returned to pretreatment levels within 4-13 weeks. Plasma insulin levels also were suppressed but only during the first 3-5 days of treatment. Plasma EGF-TGF-a levels increased significantly at day 5 of treatment only in the pancreatic cancer patients. Twenty-seven per ceht of the patients showed stable disease for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects. However, the overall survival remained disappointing, emphasising the need for better treatment regimens.

show abstract

mentioning

confidence: 99%

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

Klijn

Hoff²,

Planting³

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

167 effect of gastrointestinal hormones on the growth of gastrointestinal tumor cells in vitro

Cited by 1 publication

References 0 publications

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

Contact Info

Product

Resources

About